These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 35865470)

  • 1. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.
    Niu J; Peng D; Liu L
    Front Oncol; 2022; 12():896426. PubMed ID: 35865470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.
    Yao Y; Li F; Huang J; Jin J; Wang H
    Exp Hematol Oncol; 2021 Jul; 10(1):39. PubMed ID: 34246314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and Molecular State of Myeloid Leukemia Stem Cells.
    Xie X; Feng M; Wang Q; Wang J; Yin R; Li Y; Zhang H
    Adv Exp Med Biol; 2019; 1143():41-57. PubMed ID: 31338814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting.
    Chen Y; Li J; Xu L; Găman MA; Zou Z
    Cell Death Discov; 2022 Sep; 8(1):397. PubMed ID: 36163119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.
    Barbosa K; Deshpande AJ
    Front Oncol; 2023; 13():1204895. PubMed ID: 37601659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.
    van Gils N; Denkers F; Smit L
    Front Oncol; 2021; 11():659253. PubMed ID: 34012921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting acute myeloid leukemia stem cell signaling by natural products.
    Siveen KS; Uddin S; Mohammad RM
    Mol Cancer; 2017 Jan; 16(1):13. PubMed ID: 28137265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy.
    Kikushige Y
    Blood Cell Ther; 2022 Dec; 5(Spec Edition):S1-S5. PubMed ID: 37220607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
    Lim INX; Nagree MS; Xie SZ
    Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel single-cell technologies in acute myeloid leukemia research.
    Gupta SD; Sachs Z
    Transl Res; 2017 Nov; 189():123-135. PubMed ID: 28802867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
    Velasco-Hernandez T; Trincado JL; Vinyoles M; Closa A; Martínez-Moreno A; Gutiérrez-Agüera F; Molina O; Rodríguez-Cortez VC; Ximeno-Parpal P; Fernández-Fuentes N; Petazzi P; Beneyto-Calabuig S; Velten L; Romecin P; Casquero R; Abollo-Jiménez F; de la Guardia RD; Lorden P; Bataller A; Lapillonne H; Stam RW; Vives S; Torrebadell M; Fuster JL; Bueno C; Sarry JE; Eyras E; Heyn H; Menéndez P
    Hemasphere; 2024 Feb; 8(2):e45. PubMed ID: 38435427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biomarkers of leukemia stem cells in acute myeloid leukemia.
    Ding Y; Gao H; Zhang Q
    Stem Cell Investig; 2017; 4():19. PubMed ID: 28447034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theragnostic strategies harnessing the self-renewal pathways of stem-like cells in the acute myeloid leukemia.
    Bhattacharjee R; Ghosh S; Nath A; Basu A; Biswas O; Patil CR; Kundu CN
    Crit Rev Oncol Hematol; 2022 Sep; 177():103753. PubMed ID: 35803452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
    Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Lipid Metabolic Signatures in Acute Myeloid Leukemia.
    Singh P; Murali R; Shanmugam SG; Thomas S; Scott J; Warrier S; Arfuso F; Dharmarajan A; Gandhirajan RK
    Stem Cells; 2024 Mar; 42(3):200-215. PubMed ID: 38167958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.
    Zhu XN; Wei YS; Yang Q; Liu HR; Zhi Z; Zhu D; Xia L; Hong DL; Yu Y; Chen GQ
    J Hematol Oncol; 2023 Feb; 16(1):9. PubMed ID: 36774506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.